PAPILLON — Amivantamab plus Carboplatin-Pemetrexed in First-Line EGFR Exon 20 Insertion-Mutated NSCLC

Phase 3 · 2023 · Non-Small Cell Lung Cancer

Design

Randomized to amivantamab + carboplatin-pemetrexed versus carboplatin-pemetrexed alone in the first-line setting.

Population

Previously untreated advanced NSCLC with EGFR exon 20 insertion mutations.

Primary Endpoint

progression-free survival (PFS)

Key Result

Amivantamab + chemotherapy significantly improved PFS versus chemotherapy alone (median 11.4 vs 6.7 mo; HR 0.40) in first-line EGFR exon 20 insertion NSCLC.

Guideline Impact

First-line EGFR exon 20 insertion advanced NSCLC